Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in NeoGenomics, Inc. or Aveanna Healthcare Holdings Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc. compare based on key financial metrics to determine which better meets your investment needs.

About NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Latest Health Care Providers & Services and NeoGenomics, Inc., Aveanna Healthcare Holdings Inc. Stock News

As of July 30, 2026, NeoGenomics, Inc. had a $2.0 billion market capitalization, compared to the Health Care Providers & Services median of $1.9 million. NeoGenomics, Inc.’s stock is up 32.3% in 2026, up 12% in the previous five trading days and up 202.48% in the past year.

Currently, NeoGenomics, Inc. does not have a price-earnings ratio. NeoGenomics, Inc.’s trailing 12-month revenue is $766.3 million with a -6.8% net profit margin. Year-over-year quarterly sales growth most recently was 11.3%. Analysts expect adjusted earnings to reach $0.183 per share for the current fiscal year. NeoGenomics, Inc. does not currently pay a dividend.

As of July 30, 2026, Aveanna Healthcare Holdings Inc. had a $2.1 billion market cap, putting it in the 55th percentile of all stocks. Aveanna Healthcare Holdings Inc.’s stock is up 14.6% in 2026, down 1% in the previous five trading days and up 141.05% in the past year.

Currently, Aveanna Healthcare Holdings Inc.’s price-earnings ratio is 8.1. Aveanna Healthcare Holdings Inc.’s trailing 12-month revenue is $2.5 billion with a 10.4% net profit margin. Year-over-year quarterly sales growth most recently was 15.9%. Analysts expect adjusted earnings to reach $0.707 per share for the current fiscal year. Aveanna Healthcare Holdings Inc. does not currently pay a dividend.

How We Compare NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc. Stock Value Grades

Company	Ticker	Value
NeoGenomics, Inc.	NEO	F
Aveanna Healthcare Holdings Inc.	AVAH	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

NeoGenomics, Inc. has a Value Score of 20, which is Ultra Expensive. Aveanna Healthcare Holdings Inc. has a Value Score of 57, which is Average.

The Value Stock Winner: No Clear Winner

Neither NeoGenomics, Inc. or Aveanna Healthcare Holdings Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if NeoGenomics, Inc. or Aveanna Healthcare Holdings Inc. is the better investment when it comes to value.

NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc. Growth Grades

Company	Ticker	Growth
NeoGenomics, Inc.	NEO	C
Aveanna Healthcare Holdings Inc.	AVAH	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

NeoGenomics, Inc. has a Growth Score of 48, which is Average. Aveanna Healthcare Holdings Inc. has a Growth Score of 64, which is Strong.

The Growth Grade Winner: Aveanna Healthcare Holdings Inc.

As you can clearly see from the Growth Grade breakdown above, Aveanna Healthcare Holdings Inc. has a more attractive growth grade than NeoGenomics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Aveanna Healthcare Holdings Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc.’s Quality Grades

Company	Ticker	Quality
NeoGenomics, Inc.	NEO	C
Aveanna Healthcare Holdings Inc.	AVAH	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

NeoGenomics, Inc. has a Quality Score of 53, which is Average. Aveanna Healthcare Holdings Inc. has a Quality Score of 73, which is Strong.

The Quality Grade Winner: Aveanna Healthcare Holdings Inc.

As you can clearly see from the Quality Grade breakdown above, Aveanna Healthcare Holdings Inc. has a better overall quality grade than NeoGenomics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Aveanna Healthcare Holdings Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc. Grades

In addition to Quality, Growth and Value, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, NeoGenomics, Inc. or Aveanna Healthcare Holdings Inc. Stock?

Overall, NeoGenomics, Inc. stock has a Value Score of 20, Growth Score of 48 and Quality Score of 53.

Aveanna Healthcare Holdings Inc. stock has a Value Score of 57, Growth Score of 64 and Quality Score of 73.

Comparing NeoGenomics, Inc. and Aveanna Healthcare Holdings Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.